CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$1.92 USD
-0.02 (-1.03%)
Updated Apr 25, 2024 03:59 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Price, Consensus and EPS Surprise
CANF 1.92 -0.02(-1.03%)
Will CANF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CANF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CANF
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CANF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 27th
New Strong Buy Stocks for October 27th
Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer
Other News for CANF
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Can-Fite Reports Breakthrough in Liver Cancer Treatment
Can-Fite BioPharma publishes article relating to namodenoson
Can-Fite’s Namodenoson Shows Promise for Liver Cancer